HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: An updated review

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Cheng, Chi Yuan ^a   Su, Shih Chi ^a   Chen, Chi Hua ^a   Chen, Wei Li ^a   Deng, Shin Tarng ^a   Chung, Wen Hung ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; CARBAMAZEPINE; DAPSONE; HLA B15 ANTIGEN; LAMOTRIGINE; NEVIRAPINE; OXCARBAZEPINE; PHENYTOIN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; HLA ANTIGEN;

DELAYED HYPERSENSITIVITY; DISEASE ASSOCIATION; DRESS SYNDROME; DRUG HYPERSENSITIVITY; ETHNICITY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HLA SYSTEM; HUMAN; PHARMACOGENETICS; PHENOTYPE; REVIEW; SEVERE CUTANEOUS ADVERSE REACTION; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS; ALLELE; DRUG EFFECTS; DRUG HYPERSENSITIVITY SYNDROME; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PATHOLOGY; STEVENS-JOHNSON SYNDROME;

ALLELES; ALLOPURINOL; CARBAMAZEPINE; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY SYNDROME; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; STEVENS-JOHNSON SYNDROME; T-LYMPHOCYTES;

EID: 84901804301     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/565320     Document Type: Review

References (63)

1. Roujeau J. C., Stern R. S., Severe adverse cutaneous reactions to drugs. The New England Journal of Medicine 1994 331 19 1272 1285 2-s2.0-0028077408 10.1056/NEJM199411103311906 (Pubitemid 24333193)
2. Bastuji-Garin S., Rzany B., Stern R. S., Shear N. H., Naldi L., Roujeau J.-C., Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Archives of Dermatology 1993 129 1 92 96 2-s2.0-0027500068 10.1001/archderm.129.1.92 (Pubitemid 23029676)
3. Chan H. L., Stern R. S., Arndt K. A., Langlois J., Jick S. S., Jick H., Walker A. M., The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Archives of Dermatology 1990 126 1 43 47 2-s2.0-0025166471 10.1001/archderm.126.1.43 (Pubitemid 20040979)
4. Shiohara T., Inaoka M., Kano Y., Drug-induced hypersensitivity syndrome(DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergology International 2006 55 1 1 8 2-s2.0-33645764109 10.2332/allergolint.55.1
5. Kano Y., Hiraharas K., Sakuma K., Shiohara T., Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. British Journal of Dermatology 2006 155 2 301 306 2-s2.0-33745926866 10.1111/j.1365-2133.2006.07238.x (Pubitemid 44050562)
6. Tohyama M., Hashimoto K., Yasukawa M., Kimura H., Horikawa T., Nakajima K., Urano Y., Matsumoto K., Iijima M., Shear N. H., Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. British Journal of Dermatology 2007 157 5 934 940 2-s2.0-35348921366 10.1111/j.1365-2133.2007.08167.x (Pubitemid 47583515)
7. Eshki M., Allanore L., Musette P., Milpied B., Grange A., Guillaume J.-C., Chosidow O., Guillot I., Paradis V., Joly P., Crickx B., Ranger-Rogez S., Descamps V., Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Archives of Dermatology 2009 145 1 67 72 2-s2.0-58849091724 10.1001/archderm.145.1.67
8. Chung W.-H., Hung S.-I., Hong H.-S., Hsih M.-S., Yang L.-C., Ho H.-C., Wu J.-Y., Chen Y.-T., Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004 428 6982 486 2-s2.0-1842484777 (Pubitemid 38480527)
9. Chung W.-H., Hung S.-I., Yang J.-Y., Su S.-C., Huang S.-P., Wei C.-Y., Chin S.-W., Chiou C.-C., Chu S.-C., Ho H.-C., Yang C.-H., Lu C.-F., Wu J.-Y., Liao Y.-D., Chen Y.-T., Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nature Medicine 2008 14 12 1343 1350 2-s2.0-57349198641 10.1038/nm.1884
10. Leckband S. G., Kelsoe J. R., Dunnenberger H. M., Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing. Clinical Pharmacology & Therapeutics 2013 94 3 324 328 10.1038/clpt.2013.103
11. Chen P., Lin J.-J., Lu C.-S., Ong C.-T., Hsieh P. F., Yang C.-C., Tai C.-T., Wu S.-L., Lu C.-H., Hsu Y.-C., Yu H.-Y., Ro L.-S., Lu C.-T., Chu C.-C., Tsai J.-J., Su Y.-H., Lan S.-H., Sung S.-F., Lin S.-Y., Chuang H.-P., Huang L.-C., Chen Y.-J., Tsai P.-J., Liao H.-T., Lin Y.-H., Chen C.-H., Chung W.-H., Hung S.-I., Wu J.-Y., Chang C.-F., Chen L., Chen Y.-T., Shen C.-Y., Carbamazepine-induced toxic effects and HLA-B1502 screening in Taiwan. The New England Journal of Medicine 2011 364 12 1126 1133 2-s2.0-79953216429 10.1056/NEJMoa1009717
12. Schoonen W. M., Thomas S. L., Somers E. C., Smeeth L., Kim J., Evans S., Hall A. J., Do selected drugs increase the risk of lupus? A matched case-control study. British Journal of Clinical Pharmacology 2010 70 4 588 596 2-s2.0-77956604471 10.1111/j.1365-2125.2010.03733.x
13. Hung S.-I., Chung W.-H., Jee S.-H., Chen W.-C., Chang Y.-T., Lee W.-R., Hu S.-L., Wu M.-T., Chen G.-S., Wong T.-W., Hsiao P.-F., Chen W.-H., Shih H.-Y., Fang W.-H., Wei C.-Y., Lou Y.-H., Huang Y.-L., Lin J.-J., Chen Y.-T., Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics 2006 16 4 297 306 2-s2.0-33645082244 10.1097/01.fpc.0000199500.46842.4a
14. Man C. B., Kwan P., Baum L., Yu E., Lau K. M., Cheng A. S. H., Ng M. H. L., Association between HLA-B1502 allele and antiepileptic drugs-induced cutaneous reactions in Han Chinese. Epilepsia 2007 48 5 1015 1018 (Pubitemid 46763406)
15. Chung W.-H., Hung S.-I., Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. Journal of Dermatological Science 2012 66 3 190 196 2-s2.0-84859931878 10.1016/j.jdermsci. 2012.04.002
16. Yip V. L., Marson A. G., Jorgensen A. L., Pirmohamed M., Alfirevic A., HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clinical Pharmacology & Therapeutics 2012 92 6 757 765
17. Tangamornsuksan W., Chaiyakunapruk N., Somkrua R., Lohitnavy M., Tassaneeyakul W., Relationship between the HLA-B1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatology 2013 149 9 1025 1032 10.1001/jamadermatol.2013.4114
18. Ozeki T., Mushiroda T., Yowang A., Takahashi A., Kubo M., Shirakata Y., Ikezawa Z., Iijima M., Shiohara T., Hashimoto K., Kamatani N., Nakamura Y., Genome-wide association study identifies HLA-A3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Human Molecular Genetics 2011 20 5 1034 1041 2-s2.0-79551600984 10.1093/hmg/ddq537
19. McCormack M., Alfirevic A., Bourgeois S., HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans. The New England Journal of Medicine 2011 364 12 1134 1143 2-s2.0-79953197983 10.1056/NEJMoa1013297
20. Genin E., Chen D. P., Hung S. I., HLA-A31: 01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. The Pharmacogemonics Journal 2013 10.1038/tpj.2013.40
21. Hsiao Y.-H., Hui R. C.-Y., Wu T., Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. Journal of Dermatological Science 2014 73 2 101 109
22. Kim S.-H., Lee K. W., Song W.-J., Kim S.-H., Jee Y.-K., Lee S.-M., Kang H.-R., Park H.-W., Cho S.-H., Park S.-H., Min K.-U., Chang Y.-S., Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Research 2011 97 1 190 197 2-s2.0-81055156142 10.1016/j.eplepsyres.2011.08.010
23. Kaniwa N., Saito Y., Aihara M., Matsunaga K., Tohkin M., Kurose K., Furuya H., Takahashi Y., Muramatsu M., Kinoshita S., Abe M., Ikeda H., Kashiwagi M., Song Y., Ueta M., Sotozono C., Ikezawa Z., Hasegawa R., HLA-B1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010 51 12 2461 2465 2-s2.0-78650007285 10.1111/j.1528-1167.2010.02766.x
24. Shi Y.-W., Min F.-L., Qin B., Zou X., Liu X.-R., Gao M.-M., Wang Q., Zhou J.-Q., Liao W.-P., Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B1502? Basic & Clinical Pharmacology & Toxicology 2012 111 1 58 64 2-s2.0-84858205452 10.1111/j.1742-7843.2012.00868.x
25. Ikeda H., Takahashi Y., Yamazaki E., Fujiwara T., Kaniwa N., Saito Y., Aihara M., Kashiwagi M., Muramatsu M., HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010 51 2 297 300 2-s2.0-75649107833 10.1111/j.1528-1167.2009.02269.x
26. Wei C.-Y., Chung W.-H., Huang H.-W., Chen Y.-T., Hung S.-I., Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. The Journal of Allergy and Clinical Immunology 2012 129 6 1562 1569.e5 2-s2.0-84856587285 10.1016/j.jaci.2011.12.990
27. Cheung Y.-K., Cheng S.-H., Chan E. J. M., Lo S. V., Ng M. H. L., Kwan P., HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013 54 7 1307 1314 10.1111/epi.12217
28. Alfirevic A., Jorgensen A. L., Williamson P. R., Chadwick D. W., Park B. K., Pirmohamed M., HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006 7 6 813 818 2-s2.0-33748987340 10.2217/14622416.7.6.813 (Pubitemid 44446732)
29. Su S.-C., Chung W.-H., Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatologica Sinica 2013 31 4 175 180 10.1016/j.dsi.2013.09.002
30. Hung S.-I., Chung W.-H., Liu Z.-S., Chen C.-H., Hsih M.-S., Hui R. C.-Y., Chu C.-Y., Chen Y.-T., Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010 11 3 349 356 2-s2.0-77949600882 10.2217/pgs.09.162
31. Locharernkul C., Loplumlert J., Limotai C., Korkij W., Desudchit T., Tongkobpetch S., Kangwanshiratada O., Hirankarn N., Suphapeetiporn K., Shotelersuk V., Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B1502 allele in Thai population. Epilepsia 2008 49 12 2087 2091 2-s2.0-57449118501 10.1111/j.1528-1167.2008.01719.x
32. Hershfield M. S., Callaghan J. T., Tassanccyakul W., Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clinical Pharmacology & Therapeutics 2013 93 2 153 158
33. Hung S.-L., Chung W.-H., Liou L.-B., Chu C.-C., Lin M., Huang H.-P., Lin Y.-L., Lan J.-L., Yang L.-C., Hong H.-S., Chen M.-J., Lai P.-C., Wu M.-S., Chu C.-Y., Wang K.-H., Chen C.-H., Fann C. S. J., Wu J.-Y., Chen Y.-T., HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences of the United States of America 2005 102 11 4134 4139 2-s2.0-15244349566 10.1073/pnas. 0409500102 (Pubitemid 40388568)
34. Somkrua R., Eickman E. E., Saokaew S., Lohitnavy M., Chaiyakunapruk N., Association of HLA-B5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Medical Genetics 2011 12, article 118 2-s2.0-80052596861 10.1186/1471-2350-12- 118
35. Lee M., Chen Y., Shen C. A., A prospective study of HLA-B5801 genotyping for the prevention of allopurinol induced severe cutaneous adverse reactions. Proceedings of the113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics March 2012 National Harbor, Maryland abstract S107
36. Tassaneeyakul W., Jantararoungtong T., Chen P., Lin P.-Y., Tiamkao S., Khunarkornsiri U., Chucherd P., Konyoung P., Vannaprasaht S., Choonhakarn C., Pisuttimarn P., Sangviroon A., Tassaneeyakul W., Strong association between HLA-B5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenetics and Genomics 2009 19 9 704 709 2-s2.0-70249122727 10.1097/FPC.0b013e328330a3b8
37. Cao Z.-H., Wei Z.-Y., Zhu Q.-Y., HLA-B58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics 2012 13 10 1193 1201 10.2217/pgs.12.89
38. Lee M. H., Stocker S. L., Anderson J., Phillips E. J., Nolan D., Williams K. M., Graham G. G., Sullivan J. R., Day R. O., Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? Internal Medicine Journal 2012 42 4 411 416 2-s2.0-84859835143 10.1111/j.1445-5994.2011. 02567.x
39. Khanna D., Fitzgerald J. D., Khanna P. P., 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research 2012 64 10 1431 1446
40. Chohan S., Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. The Journal of Rheumatology 2011 38 9 1957 1959 2-s2.0-80052337433 10.3899/jrheum.110092
41. Sundy J. S., Baraf H. S., Yood R. A., Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. The Journal of the American Medical Association 2011 306 7 711 720 2-s2.0-80051749331 10.1001/jama.2011.1169
42. Jung J.-W., Song W.-J., Kim Y.-S., Joo K. W., Lee K. W., Kim S.-H., Park H.-W., Chang Y.-S., Cho S.-H., Min K.-U., Kang H.-R., HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrology Dialysis Transplantation 2011 26 11 3567 3572 2-s2.0-80155198743 10.1093/ndt/gfr060
43. Hetherington S., McGuirk S., Powell G., Cutrell A., Naderer O., Spreen B., Lafon S., Pearce G., Steel H., Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clinical Therapeutics 2001 23 10 1603 1614 2-s2.0-0035163638 10.1016/S0149-2918(01)80132- 6 (Pubitemid 33063588)
44. Shapiro M., Ward K. M., Stern J. J., A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Reader 2001 11 4 222 226 2-s2.0-0035064040 (Pubitemid 32332270)
45. Bossi P., Roujeau J. C., Bricaire F., Caumes E., Stevens-Johnson syndrome associated with abacavir therapy. Clinical Infectious Diseases 2002 35 7 902 2-s2.0-0036788429
46. Pahk R., Azu M. C., Taira B. R., Sandoval S., Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus. Clinical and Experimental Dermatology 2009 34 8 e775 e777 2-s2.0-72549119546 10.1111/j.1365-2230.2009.03508.x
47. Hetherington S., Hughes A. R., Mosteller M., Shortino D., Baker K. L., Spreen W., Lai E., Davies K., Handley A., Dow D. J., Fling M. E., Stocum M., Bowman C., Thurmond L. M., Roses A. D., Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. The Lancet 2002 359 9312 1121 1122 2-s2.0-0037197044 10.1016/S0140-6736(02)08158-8 (Pubitemid 34270738)
48. Mallal S., Nolan D., Witt C., Masel G., Martin A. M., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., Christiansen F. T., Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. The Lancet 2002 359 9308 727 732 2-s2.0-0037006623 10.1016/S0140-6736(02)07873-X (Pubitemid 34215071)
49. Gatanaga H., Honda H., Oka S., Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 2008 9 2 207 214 2-s2.0-42449120613 10.2217/14622416.9.2.207 (Pubitemid 351566944)
50. Hughes A. R., Mosteller M., Bansal A. T., Davies K., Haneline S. A., Lai E. H., Nangle K., Scott T., Spreen W. R., Warren L. L., Roses A. D., Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004 5 2 203 211 2-s2.0-12144291646 10.1517/phgs.5.2.203.27481 (Pubitemid 38351278)
51. Mallal S., Phillips E., Carosi G., HLA-B5701 screening for hypersensitivity to abacavir. The New England Journal of Medicine 2008 358 6 568 579 2-s2.0-38949196447 10.1056/NEJMoa0706135 (Pubitemid 351214284)
52. Phillips E. J., Sullivan J. R., Knowles S. R., Shear N. H., Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002 16 16 2223 2225 2-s2.0-0037045073 10.1097/00002030- 200211080-00017 (Pubitemid 35387279)
53. Phillips E. J., Wong G. A., Kaul R., Shahabi K., Nolan D. A., Knowles S. R., Martin A. M., Mallal S. A., Shear N. H., Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005 19 9 979 981 2-s2.0-20644470742 (Pubitemid 40834943)
54. Shear N. H., Milpied B., Bruynzeel D. P., Phillips E. J., A review of drug patch testing and implications for HIV clinicians. AIDS 2008 22 9 999 1007 2-s2.0-44449113606 10.1097/QAD.0b013e3282f7cb60 (Pubitemid 351769738)
55. Phillips E. J., Mallal S. A., Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010 11 7 973 987 2-s2.0-77954365622 10.2217/pgs.10.77
56. Martin A. M., Nolan D., James I., Cameron P., Keller J., Moore C., Phillips E., Christiansen F. T., Mallal S., Predisposition to nevirapine hypersensitivity associated with HLA-DRB10101 and abrogated by low CD4 T-cell counts. AIDS 2005 19 1 97 99 2-s2.0-12144260460 (Pubitemid 40111026)
57. Chantarangsu S., Mushiroda T., Mahasirimongkol S., Kiertiburanakul S., Sungkanuparph S., Manosuthi W., Tantisiriwat W., Charoenyingwattana A., Sura T., Chantratita W., Nakamura Y., HLA-B3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenetics and Genomics 2009 19 2 139 146 2-s2.0-59549096348 10.1097/FPC.0b013e32831d0faf
58. Littera R., Carcassi C., Masala A., Piano P., Serra P., Ortu F., Corso N., Casula B., la Nasa G., Contu L., Manconi P. E., HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006 20 12 1621 1626 2-s2.0-33746767604 10.1097/01.aids.0000238408.82947.09 (Pubitemid 44162404)
59. Gatanaga H., Yazaki H., Tanuma J., Honda M., Genka I., Teruya K., Tachikawa N., Kikuchi Y., Oka S., HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007 21 2 264 265 2-s2.0-33845945094 10.1097/QAD.0b013e32801199d9 (Pubitemid 46036947)
60. Ciccacci C., di Fusco D., Marazzi M. C., Association between CYP2B6 polymorphisms and nevirapine-induced SJS/TEN: a pharmacogenetics study. European Journal of Clinical Pharmacology 2013 69 11 1909 1916 10.1007/s00228-013-1549-x
61. Zhang F.-R., Liu H., Irwanto A., HLA-B13:01 and the dapsone hypersensitivity syndrome. The New England Journal of Medicine 2013 369 17 1620 1628 10.1056/NEJMoa1213096
62. Sacco J. C., Abouraya M., Motsinger-Reif A., Yale S. H., McCarty C. A., Trepanier L. A., Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity. Pharmacogenetics and Genomics 2012 22 10 733 740 10.1097/FPC.0b013e328357a735
63. Lee A.-Y., Kim M.-J., Chey W.-Y., Choi J., Kim B.-G., Genetic polymorphism of cytochrome P 450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. European Journal of Clinical Pharmacology 2004 60 3 155 159 2-s2.0-2942560855 10.1007/s00228-004-0753-0 (Pubitemid 38757125)